

LaVoie Group Newsletter

The Acknowledged Leader in Life Science Communications

SPRING 2008

In This Issue

LaVoie Group Adds Silence Therapeutics and Interleukin Genetics to its Life Science Agency Roster

LaVoie Group Appoints Catherine Cloft, Industry Veteran, as Vice President

Donna L. LaVoie to Lead Investor Relations Panel at BIO 2008 International Convention 2008

Quick Links

[Fact Sheet](#)
[Meet the Team](#)
[Case Studies](#)

Greetings:

LaVoie Group launched the first version of its ***Life Sciences Events Planning Calendar*** one year ago. This calendar has grown in scale, making conference planning for life science companies easier.

LaVoie Group's calendar features key industry events, medical, partnering and investor meetings. Since our last update, we've added second half of 2008 events. We encourage you to utilize this calendar and return regularly for updates at www.lavoiegroup.com.

Sincerely,



Donna L. LaVoie
President & CEO

LaVoie Group Adds Silence Therapeutics and Interleukin Genetics to its Life Science Agency Roster

LaVoie Group today announced that it has been selected as public relations agency of record by Silence Therapeutics plc (London LSE:SLN) and Interleukin Genetics (AMEX:ILL).

Donna L. LaVoie, President & CEO, commented, "We are delighted to be working on the leading edge of the life sciences sector. As a leader in RNA therapeutics and delivery, Silence Therapeutics' strategy is a combination of partnerships and proprietary pipeline development. We look forward to representing them as their U.S. public relations counsel."

Ms. LaVoie continued, "With personalized medicine top of mind across a number of different constituencies, Interleukin Genetics is well positioned to capitalize on its strengths in genetics research to develop and test innovative preventive and therapeutic products. LaVoie Group looks forward to working with the company to communicate its story."

LaVoie Group Appoints Catherine Cloft, Industry Veteran, as Vice President

Catherine Cloft joins LaVoie Group as Vice President. As a senior counselor, Catherine will work across accounts and with the LaVoie Group team.

Catherine comes to us from Nucryst Pharmaceuticals, where she was Associate Director, Communications, Marketing, & Business Development. She has a strong life sciences background having worked at several companies including Apothecom LLC, a medical communications agency, Connetics Corporation, Abbott Laboratories, Codman and Surtleff, and Surikos. She holds an M.B.A. in Finance and an undergraduate degree in English and Marketing.



Catherine brings to LaVoie Group:

- Strong relationships with key constituencies including media, investors and key opinion leaders
- Breadth of therapeutic experience (dermatology, cardiovascular, gastroenterology, pulmonary, allergy, general medicine, rheumatology, neurology, psychiatry, neurology, neurosurgery)
- Understanding of the communication needs and challenges of early stage companies
- IPO and investor relations experience
- Variety of communication writing
- Website design and management
- Industry knowledge
- Strategic, corporate and medical communications

Donna L. LaVoie to Lead Investor Relations Panel at BIO 2008 International Convention 2008

At the BIO 2008 International Convention to be held in San Diego, CA from June 17-20, Donna LaVoie will lead a panel titled, "Investor Relations Practices Across Market-Cap Companies." The panel will take place on Thursday, June 19 from 10:30 a.m. - 12:00 p.m. The session will be held at the San Diego Convention Center in room 27 AB. Panelists include: Michael Partridge, Sr. Dir., Strategic Communications, Vertex Pharmaceuticals, Inc.; Rebecca Peterson, VP, Corp. Comm., Alkermes, Inc. and Michelle Dipp, M.D., Ph.D, Dir. Corp. Development, Sirtris Pharmaceuticals, Inc. For more information, please click [here](#).